Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9019002 | 1.00 | THRB (0.35) | THRBLMNA | |
| SCHEMBL6249034 | 0.87 | — | — | |
| SCHEMBL9366414 | 0.81 | THRB (0.32) | THRBLMNA | |
| SCHEMBL6130690 | 0.81 | THRB (0.32) | THRBLMNA | |
| SCHEMBL9018986 | 0.77 | — | — | |
| SCHEMBL1484476 | 0.77 | — | — | |
| SCHEMBL9019150 | 0.77 | — | — | |
| SCHEMBL9019024 | 0.73 | — | — | |
| SCHEMBL9019000 | 0.73 | — | — | |
| SCHEMBL4842907 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312474-A1 | ANTHRACYCLINS AND CONJUGATES THEREOF | SYNAFFIX B.V. (NL) | 2025-10-09 | — | — | US | disclosed |
| EP-4572798-A1 | ANTHRACYCLINS AND CONJUGATES THEREOF | Synaffix B.V. (NL) | 2025-06-25 | — | — | EP | disclosed |
| CN-119997985-A | Anthracyclines and conjugates thereof | 西纳福克斯股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2024038065-A1 | ANTHRACYCLINS AND CONJUGATES THEREOF | SYNAFFIX B.V. (NL) | 2024-02-22 | — | — | WO | disclosed |
| EP-0434960-B1 | Chiral 1,5-diiodo-2-methoxy or benzyloxy intermediates | PHARMACIA SPA (IT) | 1996-09-18 | — | — | EP | disclosed |
| US-5304687-A | 1-alkoxy-2,2*-diiodo-diethyl ether which reacts with doxorubicin to yield anthrocycline antibiotics | FARMITALIA CARLO ERBA S.R.L. (IT) | 1994-04-19 | — | — | US | disclosed |
| EP-0434960-A1 | Chiral 1,5-diiodo-2-methoxy or benzyloxy intermediates | PHARMACIA S.p.A. (IT) | 1991-07-03 | — | — | EP | disclosed |
| WO-1991009046-A1 | MORPHOLINYL DERIVATIVES OF DOXORUBICIN AND PROCESS FOR THEIR PREPARATION | FARMITALIA CARLO ERBA S.R.L. (IT) | 1991-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312474-A1 | ANTHRACYCLINS AND CONJUGATES THEREOF | ANTXR2, NCL, DUT | THRB 4219/4885LMNA 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.